



March 2, 2016

NeuroMetrix Announces Availability of the Newest Version of Quell® Wearable Pain Relief Technology™

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a major upgrade to the Quell Wearable Pain Relief technology has started shipping to consumers and healthcare providers. The latest version of the company's over-the-counter, 100% drug free chronic pain relief wearable received a 510(k) clearance (K152954) from the U.S. Food and Drug Administration (FDA) in January 2016. The Quell device is now more fully integrated with the Quell Relief smartphone app to provide an unprecedented level of convenience and comfort for people using Quell to treat chronic pain. With the recently released update to Quell Relief, app users can also gain deeper insight into sleep, thanks to Quell's advanced sleep tracking capabilities, which are unique within the wearables category.

"One of the most common requests of Quell users was to be able to discreetly manage therapy from their smartphone," said Shai Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We are delighted to empower Quell users to regain even more control and insight into their pain management regimen through continued innovation including smartphone control and advanced sleep tracking. Quell continues to make a meaningful difference for people with chronic pain."

Quell is designed for millions of people suffering from chronic pain. The latest version of Quell gives users the option to start, stop, and adjust therapy discreetly via their smartphone. It also enables advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Additional enhancements include extending battery life by up to 25% and the ability to review historical trends in various time increments. NeuroMetrix will announce details of an upgrade program for current Quell users in April 2016.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160302005236/en/>

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media